- Home
- SG vs RIGL Comparison
SG vs RIGL Comparison
Compare SG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SG | RIGL |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 564.7M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SG | RIGL |
|---|---|---|
| Price | $8.10 | $30.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 3 |
| Target Price | $8.43 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 6.6M | 394.8K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | ★ 1.05 | 0.44 |
| Revenue | ★ $679,474,000.00 | $294,282,000.00 |
| Revenue This Year | $7.60 | N/A |
| Revenue Next Year | $8.45 | $12.75 |
| P/E Ratio | ★ $7.14 | $68.36 |
| Revenue Growth | 0.39 | ★ 64.15 |
| 52 Week Low | $4.49 | $18.14 |
| 52 Week High | $16.70 | $52.24 |
Technical Indicators
Market Signals| Indicator | SG | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 58.74 |
| Support Level | $6.39 | $28.14 |
| Resistance Level | $9.14 | $31.22 |
| Average True Range (ATR) | 0.84 | 1.19 |
| MACD | -0.26 | 0.14 |
| Stochastic Oscillator | 23.69 | 96.94 |
Price Performance
Historical ComparisonAbout SG Sweetgreen Inc.
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing. Its menu involves, Kids' meal, salads, sides, local items, Protein Plates, Desserts, Drinks and Others.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.